FRANKFURT (Reuters) – U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.
WASHINGTON (Reuters) – U.S. President Donald Trump has postponed a speech on lowering prescription drug prices previously scheduled for Thursday to a date in the near future, the White House said on Sunday.
LONDON (Reuters) – Shares in Prothena, a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial.
(Reuters) – Pfizer Inc said on Monday U.S. regulators declined to approve the company’s biosimilar of Roche’s blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.
(Reuters) – Pfizer Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve the company’s biosimilar to Roche’s breast cancer drug, Herceptin, and sought additional technical information.
TOKYO (Reuters) – A Japanese woman born in the final year of the 19th century and believed to have been the world’s oldest person died on Saturday, Kyodo news agency said. She was 117.
(Reuters Health) – Yoga, exercise, education and personal skills training are among the many types of interventions that may help kids improve what’s known as self-regulation, or their ability to manage their behavior and emotions, a study suggests.
(Reuters Health) – Narcotic painkillers can be particularly dangerous for patients who also take tranquilizing drugs known as benzodiazepines, but a study suggests doctors are still over-prescribing this combination of medicines.
BUDAPEST (Reuters) – A Hungarian laboratory worker has been isolated at a Budapest hospital after accidental exposure to the deadly Ebola virus but has shown no symptoms so far, health officials said on Friday.
(Reuters Health) – Many children hospitalized in the U.S. for brain injuries don’t receive all the rehabilitation services needed for them to potentially make a full recovery, a new study suggests.
BOSTON (Reuters) – Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatment…
(Reuters Health) – Older adults who lose a spouse may be more vulnerable to cognitive decline in subsequent years and require extra support and monitoring, researchers say.
FRANKFURT (Reuters) – Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D.
(Reuters) – Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company’s potential blockbuster drug for spinal muscular atrophy.
(Reuters) – A federal appeals court on Thursday declared unconstitutional an Indiana law signed by then-Governor Mike Pence that banned women from having abortions because of the gender, race or disability, including Down’s syndrome, of their fetuses.
(Reuters Health) – Following practices recommended for “optimal” heart health may also reduce the risk of developing a serious heart-rhythm disorder, researchers say.
(Reuters) – An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma.
(Reuters Health) – An age-old nomadic community of Southeast Asian boat-dwellers who get their food from the sea appear to have evolved enlarged spleens that may help explain their extreme diving prowess, a new study suggests.
(Reuters) – GW Pharmaceuticals Plc’s cannabis-derived drug to treat a severe form of childhood epilepsy was unanimously backed on Thursday by an advisory panel to the U.S. Food and Drug Administration.
(Reuters) – GW Pharmaceuticals Plc’s cannabis-based drug to treat a severe form of childhood epilepsy was unanimously backed on Thursday by an advisory panel to the U.S. Food and Drug Administration.